drugset / Trial / NCT05176665
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Phase 1/2
Recruiting
152 enrolled
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Timeline
- Start
- 2021-10-21
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAFISONTAMAB | Monoclonal antibody | 1600 mg | Intravenous |